Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | METAP1 | P53582 | 2/20 | 0.48 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.46 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.46 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.46 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13363970 | 1.00 | ACHE (0.56) | ACHECYP19A1DRD2DRD3METAP1 | |
| Hydrochloric Acid SCHEMBL8870977 | 0.98 | ACHE (0.55) | ACHECYP19A1DRD2DRD3METAP1 | |
| SCHEMBL5753017 | 0.88 | CYP24A1 (0.55) | CYP19A1DRD2DRD3METAP1CYP24A1 | |
| Hydrochloric Acid SCHEMBL1813880 | 0.86 | CYP24A1 (0.54) | CYP19A1DRD2DRD3METAP1CYP24A1 | |
| SCHEMBL10206132 | 0.84 | ACHE (0.69) | ACHECYP19A1DRD2DRD3METAP1 | |
| Hydrochloric Acid SCHEMBL607143 | 0.83 | ACHE (0.67) | ACHECYP19A1DRD2DRD3METAP1 | |
| SCHEMBL5237022 | 0.83 | ACHE (0.71) | ACHECYP19A1DRD2DRD3METAP1 | |
| SCHEMBL5237018 | 0.83 | ACHE (0.71) | ACHECYP19A1DRD2DRD3METAP1 | |
| SCHEMBL5237012 | 0.83 | ACHE (0.71) | ACHECYP19A1DRD2DRD3METAP1 | |
| SCHEMBL3875408 | 0.81 | ACHE (0.56) | ACHECYP19A1DRD2DRD3METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684953-B1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | KANEKA CORP (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9029113-B2 | Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same | KANEKA CORPORATION (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-2684953-A1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | Kaneka Corporation (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20140004575-A1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | KANEKA CORPORATION (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| EP-1317459-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020530-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | ACHE 597/4885CYP19A1 2176/4885DRD2 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.